Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Alberto S. Pappo

Pediatric Hematology Oncology

262 Danny Thomas Pl,

Memphis, TN

35 Years of Experience

Distinguished in Embryonal Tumor with Multilayered Rosettes

262 Danny Thomas Pl,

Memphis, TN

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Alberto Pappo is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Pappo has been practicing medicine for over 35 years and is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 183 peer reviewed articles and participating in 25 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 16 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield

Cigna

Locations

262 Danny Thomas Pl, Memphis, TN 38105

Call: 901-595-6765

Additional Areas of Focus

Dr. Pappo has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Active_not_recruiting

Publish Date: September 24, 2025

Intervention Type: Other, Drug

Study Drug: Ulixertinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Study ITCC-054/COG-AAML1921

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug

Study Drug: Bosutinib

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Tipifarnib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Drug

Study Drug: Ivosidenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Procedure, Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: June 22, 2025

Intervention Type: Drug

Study Drug: Larotrectinib (Vitravki, BAY2757556)

Study Phase: Phase 1/Phase 2

Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Enrollment Status: Active_not_recruiting

Publish Date: June 11, 2025

Intervention Type: Drug

Study Drug: Larotrectinib Sulfate

Study Phase: Phase 2

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: April 23, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study

Enrollment Status: Active_not_recruiting

Publish Date: April 10, 2025

Intervention Type: Other, Procedure

Study Phase: Not Applicable

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Procedure, Drug

Study Drug: Samotolisib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Other, Drug

Study Drug: Vemurafenib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex

Enrollment Status: Completed

Publish Date: January 27, 2025

Intervention Type: Drug

Study Drug: Tazemetostat

Study Phase: Phase 2

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Drug, Procedure

Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes

Enrollment Status: Completed

Publish Date: December 11, 2024

Intervention Type: Drug

Study Drug: Olaparib

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes

Enrollment Status: Completed

Publish Date: November 01, 2024

Intervention Type: Other, Drug

Study Drug: Palbociclib

Study Phase: Phase 2

A Protocol for Prospectively Collecting Fresh Tumor Tissue in Children and Adolescents With Recurrent or Progressive Solid Malignancies

Enrollment Status: Completed

Publish Date: June 06, 2023

Intervention Type: Other, Procedure

Surgical Ovarian Preservation in Females Undergoing Chemo-Radiotherapy

Enrollment Status: Completed

Publish Date: November 13, 2020

Intervention Type: Procedure

Study Phase: Not Applicable

An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma

Enrollment Status: Terminated

Publish Date: July 16, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Enrollment Status: Completed

Publish Date: June 09, 2020

Intervention Type: Drug

Study Phase: Phase 1

View 24 Less Clinical Trials

183 Total Publications

Comparing Whole-Body Diffusion-weighted MRI to Conventional Imaging: Staging Pediatric Bone and Soft-Tissue Sarcomas.

Journal: Radiology. Imaging cancer

Published: September 19, 2025

View All 183 Publications

Similar Doctors

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Amar J. Gajjar

Pediatric Hematology Oncology

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Amar J. Gajjar

Pediatric Hematology Oncology

262 Danny Thomas Pl,

Memphis, TN

(0.1 miles away)

901-595-3006

Languages Spoken:

English

See accepted insurances

Amar Gajjar is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Gajjar is rated as an Elite provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Giles W. Robinson

Pediatric Hematology Oncology

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Giles W. Robinson

Pediatric Hematology Oncology

262 Danny Thomas Pl, Mailstop 260 - St Jude Children's Research Hospital,

Memphis, TN

(0.1 miles away)

901-595-3026

Languages Spoken:

English

See accepted insurances

Giles Robinson is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Robinson is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Rhabdoid Tumor, and Glioma.

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Julie R. Park

Pediatric Hematology Oncology

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Julie R. Park

Pediatric Hematology Oncology

260 Danny Thomas Place,

Memphis, TN

(0.6 miles away)

901-595-4329

Languages Spoken:

English

See accepted insurances

Offers Telehealth

Julie Park is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Leukemia, and Osteosarcoma.

VIEW MORE EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pappo's expertise for a condition

ConditionClose